Clinical pathways have begun including financial and accountable outcome measures. As we go into 2018, these issues are expected to undergo major changes as a result of legislation and regulations coming out of Washington.
The European Medicines Agency approved its first biosimilar product in 2006; the United States biosimilar market remains in its infancy. The United States must look to the European Union as biosimilar adoption continues to grow.
As another year draws to a close, I look back on the work produced by Journal of Clinical Pathways with pride. But it is still important to keep our focus on what’s next.
As a retail provider, CVS not only has its pharmacies, which have prescribing authority in several states and can act as treatment providers in certain areas, such as vaccination. It also has the ability to operate clinics in many locations.
New developments within the parameters of clinical pathways and value-based care offer many possibilities, and the current issue of Journal of Clinical Pathways offers a wide scope of where the field stands.
Medicine changes rapidly, but you can always count on Journal of Clinical Pathways for the latest information on value-based care.
As organizations new to pathways look to develop their processes, it is highly beneficial to examine the foundations used by leaders within each therapeutic area of interest.
New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease.
Using clinical pathways to direct exactly where and when care can be best provided is critical to population health management success.
Annual updates to formulary exclusion lists suggest a need for careful evaluation by benefit sponsors, clinicians, patient advocacy groups, and the pharmaceutical industry to determine implications on treatment outcomes and achieving value-based care.